Core Insights - Novo Nordisk's triple agonist UBT251 achieved a statistically significant mean weight loss of up to 19.7% after 24 weeks in a trial conducted in China [1][2] - The trial compared three doses of UBT251 (2 mg, 4 mg, and 6 mg) against a placebo in individuals with overweight or obesity [1] Group 1 - The baseline mean body weight of participants was 92.2 kilograms, with the highest mean weight loss observed in the UBT251 group being 19.7%, compared to only 2.0% in the placebo group after 24 weeks [2]

Core Insights - Pfizer reported fourth-quarter 2025 adjusted earnings per share of 66 cents, exceeding the Zacks Consensus Estimate of 57 cents, with a year-over-year earnings increase of 5% [1] - Total revenues for the quarter were $17.6 billion, a decline of 1% year-over-year on a reported basis and 3% on an operational basis, primarily due to decreased revenues from COVID-19 products [2] Revenue Breakdown - International revenues decreased by 4% on an operational basis to $8.44 billion, while U.S. revenues fell by 1% to $9.1 billion [2] - The Primary Care segment saw a 13% operational decline in sales to $7.94 billion, while Specialty Care recorded a 6% increase to $4.77 billion, and Oncology sales rose by 8% to $4.44 billion [3] Product Performance - Eliquis sales in Primary Care rose by 8% to $2.02 billion, although alliance revenues fell short of the Zacks Consensus Estimate of $2.14 billion [4] - Global revenues from the Prevnar family increased by 8% to $1.71 billion, surpassing the Zacks Consensus Estimate of $1.65 billion [5] - Comirnaty sales were $2.27 billion, down 35% year-over-year, but still beat the Zacks Consensus Estimate of $2.0 billion [6] - Paxlovid revenues dropped by 70% year-over-year to $218 million, missing the Zacks Consensus Estimate of $289 million [7] Full-Year Results - For the full year 2025, Pfizer's sales declined by 2% to $62.6 billion, exceeding the Zacks Consensus Estimate of $61.94 billion [14] - Adjusted earnings for 2025 were $3.22 per share, a 4% increase year-over-year, beating the Zacks Consensus Estimate of $3.13 [14] 2026 Guidance - Pfizer expects total revenues for 2026 to be between $59.5 billion and $62.5 billion, reflecting a decline from 2025 due to lower COVID product revenues and an impending patent cliff [16] - COVID sales are projected to be around $5 billion in 2026, down from approximately $6.7 billion in 2025 [17] - Adjusted earnings per share for 2026 are expected to be in the range of $2.80-$3.00, a decrease from 2025's EPS of $3.22 [17] Research and Development - Pfizer plans to initiate 20 pivotal studies in 2026, including 10 for ultra-long-acting obesity candidates from the Metsera acquisition [26] - Positive top-line data from a phase IIb study on PF-08653944 showed significant weight reduction, positioning Pfizer competitively against other weight loss therapies [20][21]

Welcome back to Fast Money. Structure Therapeutic shares doubling today. The stock's best day on record.The biotech out with new data on its once daily GLP1 pill showing patients lost an average 11.3% of their body weight after 36 weeks of treatment. For more, let's bring in Missouo healthcare strategist Jared Holes. Jared, great to have you with us.Um, should Lily be concerned. Should investors in Lily be concerned about this. >> Hey Melissa, I really appreciate it.Um, maybe a little bit. I mean, structure ...

Industry Dynamics - Novo Nordisk lost to Pfizer in a $10 billion takeover battle for obesity drug developer Metsera [1] - Novo Nordisk seeks to regain lost ground in the weight-loss boom through deals [1]

Core Insights - Pfizer Inc. is acquiring obesity startup Metsera Inc. for $4.9 billion to enhance its competitive position against rival drugmakers in the weight-loss medication market [1] - The acquisition price is set at $47.50 in cash per share, with additional contingent payments of up to $22.50 per share based on the achievement of specific regulatory milestones, bringing the total potential value of the deal to $7.3 billion [1] - The deal includes a 43% premium over Metsera's closing share price on the previous Friday, indicating a strong valuation for the acquisition [1]

Clinical Trial Results - Eli Lilly's experimental pill Orphon showed an 11% weight loss in patients [1] - Novo Nordisk's weight loss shot Wegovy led to a 15% body weight reduction in trials [2] - Eli Lilly's shot Zepbound demonstrated even better weight loss results than Wegovy [2] Market Expectations and Reactions - Wall Street anticipated Orphon to perform better, aligning with injectable drugs [1] - Investors showed a negative reaction to Orphon's results, indicated by a share price decrease [1] - Pills are considered crucial for expanding market reach, in a market projected to reach $95 billion by 2030 [3] Development and Approval - Eli Lilly plans to submit Orphon's findings for approval by the end of the year [4] - The daily weight loss pill could potentially be available in pharmacies as early as 2026, pending approval [4] - Pharmaceutical companies like Pfizer and AstraZeneca have previously encountered setbacks in developing weight loss pills [3]